Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Grail, Inc. stock logo
GRAL
Grail
$40.18
+3.6%
$31.00
$12.33
$63.99
$1.45BN/A1.26 million shs779,087 shs
National HealthCare Co. stock logo
NHC
National HealthCare
$102.33
+0.7%
$95.53
$89.14
$138.49
$1.58B0.5156,514 shs26,012 shs
PACS Group, Inc. stock logo
PACS
PACS Group
$9.79
-0.1%
$10.14
$8.28
$43.92
$1.50BN/A789,990 shs404,506 shs
Personalis, Inc. stock logo
PSNL
Personalis
$4.78
+3.5%
$3.88
$1.14
$7.20
$422.19M1.831.02 million shs484,344 shs
Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Grail, Inc. stock logo
GRAL
Grail
0.00%+0.68%+6.61%-1.35%+4,017,999,900.00%
National HealthCare Co. stock logo
NHC
National HealthCare
0.00%-5.78%+8.65%+9.21%+2.72%
PACS Group, Inc. stock logo
PACS
PACS Group
0.00%-8.96%+4.93%-23.55%-64.61%
Personalis, Inc. stock logo
PSNL
Personalis
0.00%-3.43%+24.80%+1.27%+207.40%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Grail, Inc. stock logo
GRAL
Grail
0.7019 of 5 stars
1.12.00.00.03.40.80.6
National HealthCare Co. stock logo
NHC
National HealthCare
N/AN/AN/AN/AN/AN/AN/AN/A
PACS Group, Inc. stock logo
PACS
PACS Group
3.4114 of 5 stars
3.41.00.00.02.70.03.1
Personalis, Inc. stock logo
PSNL
Personalis
4.3242 of 5 stars
3.54.00.04.22.52.50.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Grail, Inc. stock logo
GRAL
Grail
2.25
Hold$31.50-21.60% Downside
National HealthCare Co. stock logo
NHC
National HealthCare
0.00
N/AN/AN/A
PACS Group, Inc. stock logo
PACS
PACS Group
2.86
Moderate Buy$34.29250.21% Upside
Personalis, Inc. stock logo
PSNL
Personalis
3.00
Buy$7.6760.39% Upside

Current Analyst Ratings Breakdown

Latest PSNL, NHC, PACS, and GRAL Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
Personalis, Inc. stock logo
PSNL
Personalis
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/14/2025
Grail, Inc. stock logo
GRAL
Grail
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$32.00 ➝ $43.00
5/7/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$8.00 ➝ $9.00
4/21/2025
Grail, Inc. stock logo
GRAL
Grail
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$32.00
4/10/2025
Personalis, Inc. stock logo
PSNL
Personalis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$7.00 ➝ $7.00
3/18/2025
Grail, Inc. stock logo
GRAL
Grail
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$16.00 ➝ $20.00
3/17/2025
Personalis, Inc. stock logo
PSNL
Personalis
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$8.00
2/28/2025
Personalis, Inc. stock logo
PSNL
Personalis
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$8.00 ➝ $8.00
2/28/2025
Personalis, Inc. stock logo
PSNL
Personalis
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$7.25 ➝ $7.00
(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Grail, Inc. stock logo
GRAL
Grail
$130.71M11.06N/AN/AN/A
National HealthCare Co. stock logo
NHC
National HealthCare
$1.37B1.15$6.53 per share15.68$59.41 per share1.72
PACS Group, Inc. stock logo
PACS
PACS Group
$3.56B0.42N/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
$85.69M4.93N/AN/A$2.64 per share1.81
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Grail, Inc. stock logo
GRAL
Grail
N/A-$60.99N/AN/AN/AN/AN/AN/A8/12/2025 (Estimated)
National HealthCare Co. stock logo
NHC
National HealthCare
$66.80M$6.9212.82N/A10.03%6.87%4.68%N/A
PACS Group, Inc. stock logo
PACS
PACS Group
$112.87MN/A0.005.500.49N/AN/AN/A5/26/2025 (Estimated)
Personalis, Inc. stock logo
PSNL
Personalis
-$108.30M-$1.29N/AN/AN/A-104.52%-66.07%-41.34%8/6/2025 (Estimated)

Latest PSNL, NHC, PACS, and GRAL Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/26/2025Q1 2025
PACS Group, Inc. stock logo
PACS
PACS Group
$0.42N/AN/AN/AN/AN/A
5/13/2025Q1 2025
Grail, Inc. stock logo
GRAL
Grail
-$4.03-$3.10+$0.93-$3.10$35.80 million$31.84 million
5/6/2025Q1 2025
Personalis, Inc. stock logo
PSNL
Personalis
-$0.23-$0.18+$0.05-$0.18$17.41 million$20.61 million
2/27/2025Q4 2024
Personalis, Inc. stock logo
PSNL
Personalis
-$0.32-$0.23+$0.09-$0.23$15.48 million$16.80 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Grail, Inc. stock logo
GRAL
Grail
N/AN/AN/AN/AN/A
National HealthCare Co. stock logo
NHC
National HealthCare
$2.562.50%+4.68%36.99%10 Years
PACS Group, Inc. stock logo
PACS
PACS Group
N/AN/AN/AN/AN/A
Personalis, Inc. stock logo
PSNL
Personalis
N/AN/AN/AN/AN/A

Latest PSNL, NHC, PACS, and GRAL Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
5/8/2025
National HealthCare Co. stock logo
NHC
National HealthCare
quarterly$0.642.7%6/30/20256/30/20258/1/2025
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Grail, Inc. stock logo
GRAL
Grail
N/A
9.65
9.65
National HealthCare Co. stock logo
NHC
National HealthCare
0.14
1.80
1.77
PACS Group, Inc. stock logo
PACS
PACS Group
0.82
1.71
1.71
Personalis, Inc. stock logo
PSNL
Personalis
N/A
4.68
4.44

Institutional Ownership

CompanyInstitutional Ownership
Grail, Inc. stock logo
GRAL
Grail
N/A
National HealthCare Co. stock logo
NHC
National HealthCare
56.44%
PACS Group, Inc. stock logo
PACS
PACS Group
N/A
Personalis, Inc. stock logo
PSNL
Personalis
61.91%

Insider Ownership

CompanyInsider Ownership
Grail, Inc. stock logo
GRAL
Grail
1.85%
National HealthCare Co. stock logo
NHC
National HealthCare
14.97%
PACS Group, Inc. stock logo
PACS
PACS Group
N/A
Personalis, Inc. stock logo
PSNL
Personalis
3.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Grail, Inc. stock logo
GRAL
Grail
1,36035.97 millionN/AOptionable
National HealthCare Co. stock logo
NHC
National HealthCare
12,40015.46 million13.32 millionN/A
PACS Group, Inc. stock logo
PACS
PACS Group
32,433152.40 millionN/AOptionable
Personalis, Inc. stock logo
PSNL
Personalis
40088.33 million67.75 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Grail stock logo

Grail NASDAQ:GRAL

$40.18 +1.41 (+3.64%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$40.44 +0.26 (+0.64%)
As of 05/23/2025 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

National HealthCare stock logo

National HealthCare NYSE:NHC

$102.33 +0.74 (+0.73%)
As of 05/23/2025 04:00 PM Eastern

National HealthCare Corporation engages in the operation of services to skilled nursing facilities, assisted and independent living facilities, homecare and hospice agencies, and health hospitals. Its skilled nursing facilities offer licensed therapy services, nutrition services, social services, activities, and housekeeping and laundry services, as well as medical services prescribed by physicians; and rehabilitative services, such as physical, speech, respiratory, and occupational therapy for patients recovering from strokes, heart attacks, orthopedic conditions, neurological illnesses, or other illnesses, injuries, or disabilities. The company's medical specialty units comprise memory care units and sub-cute nursing units that provide specialized care and programs for persons with Alzheimer's or related disorders; and assisted living facilities offer personal care services and assistance with general activities of daily living, such as dressing, bathing, meal preparation, and medication management. Its independent living facilities offers specially designed residential units for the active and ambulatory elderly and provide various ancillary services for residents, including restaurants, activity rooms and social areas; and behavioral health services to both adults and geriatric patients with psychiatric, emotional, and addictive disorders. In addition, the company's homecare agencies assist those who wish to stay at home or in assisted living residences but still require some degree of medical care or assistance with daily activities; hospice agencies that provides hospice and palliative care; and operates pharmacies, as well as managed care insurance solutions. Further, it offers management, accounting, and financial services; and leases its properties to third party operators. The company was founded in 1971 and is based in Murfreesboro, Tennessee.

PACS Group stock logo

PACS Group NYSE:PACS

$9.79 -0.01 (-0.10%)
Closing price 05/23/2025 03:59 PM Eastern
Extended Trading
$9.82 +0.03 (+0.26%)
As of 05/23/2025 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

PACS Group, Inc., through its subsidiaries, operates skilled nursing facilities and assisted living facilities in the United States. The company also provides senior care and independent facilities. It engages in the acquisition, ownership, and leasing of health care-related properties. The company was founded in 2013 and is based in Farmington, Utah.

Personalis stock logo

Personalis NASDAQ:PSNL

$4.78 +0.16 (+3.46%)
Closing price 05/23/2025 04:00 PM Eastern
Extended Trading
$4.79 +0.01 (+0.21%)
As of 05/23/2025 06:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Personalis, Inc. develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection. The company offers NeXT Personal, a tumor-informed liquid biopsy test for detection of minimal residual disease (MRD) and recurrence in cancer; and ImmunoID NeXT, a tissue-based test that combines whole exome (DNA) and whole transcriptome (RNA) sequencing data with advanced analytics to provide a multi-dimensional view of the tumor and the tumor microenvironment from a single sample. It also provides NeXT Personal Dx, a tumor-informed liquid biopsy test for detection of MRD and recurrence in cancer; and NeXT Dx, a comprehensive tumor profiling test that unlocks the entire exome (DNA) and transcriptome (RNA) with matched tumor-normal analysis. In addition, the company performs whole exome sequencing (WES) of cancer tissue and matched blood samples for diagnostic companies as an input to their products; and whole genome sequencing (WGS) on human samples for research projects, such as population sequencing initiatives, as well as offers sequencing and data analysis services to support population sequencing initiatives. Its customers include pharmaceutical companies, biopharmaceutical companies, diagnostics companies, universities, non-profits, government entities, and patients. The company was incorporated in 2011 and is headquartered in Fremont, California.